Systematic review and meta-analysis assesses mortality impact from intensified tuberculous meningitis treatment, suggesting limitations in current clinical practices.
Key Points
Intensified treatment shows no significant reduction in mortality for tuberculous meningitis patients.
Mortality odds ratios for higher-dose rifampicin were 0.86, indicating no statistical significance in treatment effects.
A systematic literature search included 10 trials with data from 1369 adults, highlighting the need for standardized case definitions.
Current evidence suggests limitations in intensified treatment due to heterogeneous outcomes and inconsistent dosing strategies.